Terms: = Uterine cancer AND SERPINE1, PAI, PAI-1, PAI1, PLANH1 AND Prognosis
16 results:
1. Identification of prognostic biomarkers for cervical cancer based on programmed cell death-related genes and assessment of their immune profile and response to drug therapy.
Feng S; Wang Z; Zhang H; Hou B; Xu Y; Hao S; Lu Y
J Gene Med; 2024 Jan; 26(1):e3643. PubMed ID: 38044747
[TBL] [Abstract] [Full Text] [Related]
2. A Cellular Senescence-Related Signature Predicts Cervical cancer Patient Outcome and Immunotherapy Sensitivity.
Shao H; Li X; Wu P; Chen Z; Zhang C; Gu H
Reprod Sci; 2023 Dec; 30(12):3661-3676. PubMed ID: 37580647
[TBL] [Abstract] [Full Text] [Related]
3. Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR).
Ye Y; Peng L; Vattai A; Deuster E; Kuhn C; Dannecker C; Mahner S; Jeschke U; von Schönfeldt V; Heidegger HH
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2189-2203. PubMed ID: 32488496
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Abbink K; Zusterzeel PLM; Geurts-Moespot A; van der Steen R; Span PN; Sweep FCGJ
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1725-1735. PubMed ID: 32394054
[TBL] [Abstract] [Full Text] [Related]
5. Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors.
Zhang G; Miyake M; Lawton A; Goodison S; Rosser CJ
BMC Cancer; 2014 May; 14():310. PubMed ID: 24885595
[TBL] [Abstract] [Full Text] [Related]
6. A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
Dariusz S; Agnieszka M; Elzbieta R; Danuta ON; Maciej Z; Piotr D; Nowicki M
Eur J Obstet Gynecol Reprod Biol; 2012 Aug; 163(2):193-9. PubMed ID: 22525297
[TBL] [Abstract] [Full Text] [Related]
7. Plasminogen activator inhibitor-1 (pai-1) 4 G/5 G polymorphism and endometrial cancer. Influence of pai-1 polymorphism on tissue pai-1 antigen and mRNA expression and tumor severity.
Gilabert-Estellés J; Ramón LA; Braza-Boïls A; Gilabert J; Chirivella M; España F; Estellés A
Thromb Res; 2012 Aug; 130(2):242-7. PubMed ID: 22055623
[TBL] [Abstract] [Full Text] [Related]
8. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (pai-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic relevance of TGF-beta1 and pai-1 in cervical cancer.
Hazelbag S; Kenter GG; Gorter A; Fleuren GJ
Int J Cancer; 2004 Dec; 112(6):1020-8. PubMed ID: 15386352
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract] [Full Text] [Related]
11. [Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia].
Gerstein ES; Gritsaenko EV; Shcherbakov ME; Shcherbakov AM; Ognerudov NA; Kushlinskiĭ NE
Vopr Onkol; 2003; 49(6):725-9. PubMed ID: 14976916
[TBL] [Abstract] [Full Text] [Related]
12. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
[TBL] [Abstract] [Full Text] [Related]
13. High tumor tissue concentration of plasminogen activator inhibitor 2 (pai-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.
Nordengren J; Fredstorp Lidebring M; Bendahl PO; Brünner N; Fernö M; Högberg T; Stephens RW; Willén R; Casslén B
Int J Cancer; 2002 Jan; 97(3):379-85. PubMed ID: 11774293
[TBL] [Abstract] [Full Text] [Related]
14. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract] [Full Text] [Related]
15. Tumor-associated proteolytic factors uPA and pai-1 in endometrial carcinoma.
Köhler U; Hiller K; Martin R; Langanke D; Naumann G; Bilek K; Jänicke F; Schmitt M
Gynecol Oncol; 1997 Aug; 66(2):268-74. PubMed ID: 9264575
[TBL] [Abstract] [Full Text] [Related]
16. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Kobayashi H; Fujishiro S; Terao T
Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
[TBL] [Abstract] [Full Text] [Related]